



TECH CENTER 1600/2900  
JAN 30 2001

RECEIVED

		ATTY. DOCKET NO. 9516-018-999	APPLICATION NO. 09/734,460
		APPLICANT Jerome B. Zeldis	
		FILING DATE December 11, 2000	GROUP To be assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CRE	AA	3,536,809	10/27/70	Applezweig			
	AB	3,598,123	8/10/71	Zaffaroni			
	AC	3,845,770	11/05/74	Theeuwes et al.			
	AD	3,916,899	11/04/75	Theeuwes et al.			
	AE	4,008,719	2/22/77	Theeuwes, et al.			
	AF	5,059,595	10/22/91	LeGrazie			
	AG	5,073,543	12/17/91	Marshall, et al.			
	AH	5,120,548	6/09/92	McClelland, et al.			
	AI	5,354,556	10/11/94	Sparks, et al.			
	AJ	5,591,767	1/07/97	Mohr, et al.			
	AK	5,593,990	1/14/97	D'Amato			
	AL	5,605,914	2/25/97	Muller			
	AM	5,629,327	5/13/97	D'Amato			
	AN	5,635,517	6/03/97	Muller et al.			
	AO	5,637,113	6/10/97	Tartaglia, et al.			
	AP	5,639,476	6/17/97	Oshlack, et al.			
	AQ	5,658,940	8/19/97	Muller et al.			
	AR	5,674,533	10/07/97	Santus et al.			
	AS	5,698,579	12/16/97	Muller			
	AT	5,703,098	12/30/97	Muller et al.			
	AU	5,728,844	3/17/98	Muller et al.			
	AV	5,728,845	3/17/98	Muller et al.			
	AW	5,733,566	3/31/98	Lewis			
	AX	5,736,570	4/07/98	Muller et al.			
	AY	5,798,368	8/25/98	Muller et al.			
	AZ	5,801,195	9/01/98	Muller et al.			
	BA	5,837,313	11/17/98	Ding et al.			
	BB	5,874,448	2/23/99	Muller et al.			
CRE	BC	5,877,200	3/02/99	Muller			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	TE	COUNTRY		CLASS	SUBCLASS	TRANSLATION
<i>CE</i>	BE	WO 99/06041	2/11/99	PCT				YES      NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>CE</i>	BE	Amols, et al., 1998, "Intracoronary radiation for prevention of restenosis: dose perturbations caused by stents", Circulation 98(19):2024-9.
JAN 16 2001 PCT	BGd	Bachelerie et al., 1991, "HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes", Nature 350(6320):709-12
<i>CE</i> SEARCHED	BI	Blaschke et al., 1979, "Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers", Arzneimittelforschung 29(10):1640-2.
	BJ	Brem, et al., 1991, "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", J Neurosurg. 74(3):441-6.
	BK	Casini, et al., 1964, Farmaco Ed. Sci. 19:563
	BL	D'Amato et al., 1994, "Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9):4082-5.
	BM	Dbaibo et al., 1993, "Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B", J Biol Chem. 268(24):17762-6.
	BN	Duh et al., 1989, "Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat", Proc Natl Acad Sci U S A. 86(15):5974-8.
	BO	Elchaninoff, et al., 1998, "Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol.32(4):980-4.
	BP	Libby et al., 1992, "A cascade model for restenosis. A special case of atherosclerosis progression", Circulation. 86(6 Suppl):III47-52.
	BQ	Moreno et al., 1996, "Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina", Circulation 94(12):3098-102.
	BR	Muller, et al. "Thalidomide: From tragedy to new drug discovery", 1997, Chemtech 27(1):21-25
	BS	Shealy et al., 1965, "D- and L-thalidomide", Chem Ind. 24:1030-1.
	BT	Suzuki and Packer. 1993, "Inhibition of NF-kappa B activation by vitamin E derivatives", Biochem Biophys Res Commun. 193(1):277-83
<i>CE</i>	BU	Takano, et al., 1998, "High levels of circulating Macrophage Colony Stimulation Factor (M-CSF) Predict Restenosis After Primary Angioplasty in Patients With Acute Myocardial Infarction", Circulation 98(17, supp):4437.
		Tardif et al., 1991, "Probuscol and multivitamins in the prevention of restenosis after coronary angioplasty", N Engl J Med. 337(6):365-72.

EXAMINER	<i>Charesse L. Evans</i>	DATE CONSIDERED	<i>3.5.2002</i>
----------	--------------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**RECEIVED** Sheet 1 of 1

MAY 17 2001

TECH CENTER 1600/2900

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.	APPLICATION NO.	
		9516-018-999	09/734,460	
		APPLICANT		
		Jerome B. Zeldis		
FILING DATE	GROUP			
December 11, 2000	1614			

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CLE	BV	5,849,736	12/15/98	Wityak et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
CLE	BW	WO 00/10552	3/2/2000	PCT			
	BX	WO 99/58096	11/18/99	PCT			
	BY	WO 98/08840	3/5/98	PCT			
	BZ	WO 96/11209	4/18/96	PCT			
CLE	CA	0 688 771	12/27/95	EPO (In German)			X

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**


EXAMINER

*Charesse L. Evans*

DATE CONSIDERED

*35.02*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.